CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study

Trial Profile

CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONSENT
  • Sponsors Merck KGaA
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint (Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period) has not been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Primary endpoint (Change From Baseline in HbA1c at Week 16) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top